Journal
ADVANCED HEALTHCARE MATERIALS
Volume 3, Issue 8, Pages 1182-1193Publisher
WILEY
DOI: 10.1002/adhm.201300607
Keywords
-
Funding
- Global Research Laboratory Project of MSIP [NRF-2013K1A1A2032346]
- GiRC Project of MSIP [2012K1A1A2A01055811]
- Korea Health Technology R&D Project of Ministry of Health Welfare [A110879]
- Intramural Research Program (Global RNAi Carrier Initiative) of KIST
- Korea Health Promotion Institute [A110879] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
RNA interference (RNAi) is a naturally occurring regulatory process that controls posttranscriptional gene expression. Small interfering RNA (siRNA), a common form of RNAi-based therapeutics, offers new opportunities for cancer therapy via silencing specific genes, which are associated to cancer progress. However, clinical applications of RNAi-based therapy are still limited due to the easy degradation of siRNA during body circulation and the difficulty in the delivery of siRNA to desired tissues and cells. Thus, there have been many efforts to develop efficient siRNA delivery systems, which protect siRNA from serum nucleases and deliver siRNA to the intracellular region of target cells. Here, the recent advances in siRNA nanocarriers, which possess tumor-targeting ability are reviewed; various nanoparticle systems and their antitumor effects are summarized. The development of multifunctional nanocarriers for theranostics or combinatorial therapy is also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available